Cullinan Oncology (CGEM)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 32/100 (MEDIUM), 22.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 17.24% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Upcoming Catalysts
- Zipalertinib — CGEM PDUFA 2027-02-27
Recent News & SEC Filings
- Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
- Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049
- Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026
- CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger
- Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs
- Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
- Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib Data
- Cullinan Therapeutics (CGEM) Reports a Six-Month PFS Gain. Can it Justify Higher Toxicity?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Cullinan Oncology.
Full CGEM Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.